June 17, 2014 – Seoul, South Korea – The InBody770 body composition analyser will be used in a validation study at the University of Erlangen in Germany.
The InBody770 premium body composition analyser will be used in a new validation study at the University of Erlangen in Germany. Dr. Simon von Stengel of the Institute of Medical Physics and Dr. Wolfgang Kemmler of the Osteoporosis Research Department will use the device in a study on sarcopenic obese people to compare such values as lean mass, fat mass, visceral fat, and bone density, and to measure the performance and risk parameters of each patient involved in the study. The authors of the study had both previously used the InBody720 and InBody230 in medical research.
The InBody770 is designed for use in sports medicine, clinical research, and patient monitoring, and has a wide range of applications as it provides a number of key parameters that can be used both in research and in practice. The device can monitor progressive change in body composition and it provides a detailed and diverse analysis that can be useful in different kinds of medical treatment, wellness advancement, and athletic development.
The device was created by BIOSPACE Co., a global leader in body composition analysis. The company is based in Seoul, Korea and has a global network of partners in more than 60 countries.
